Associated Papers
Effect of donor GSTM3 rs7483 genetic variant on tacrolimus elimination in the early period after liver transplantation.
Zhang T et al.
Peerj, 2024
39465171 (PubMed )
Supplement: peerj-12-18360-s002.7z › drug-metabolizing_enzymes_and_transporter__DMET__microarray › markerlist.xlsx › markerlist.TXT
Comprehensive analysis of important pharmacogenes in Koreans using the DMET™ platform.
Kim B et al.
Translational and Clinical Pharmacology, 2021
34621706 (PubMed )
Supplement: tcp-29-135-s001.xls › tcp-29-135-s001
Targeted sequencing identifies genetic polymorphisms of flavin-containing monooxygenase genes contributing to susceptibility of nicotine dependence in European American and African American.
Zhang TX et al.
Brain and Behavior, 2017
28413702 (PubMed )
Supplement: BRB3-7-e00651-s002.xlsx › Supplemental_Table_S1
Increased incidence of FMO1 gene single nucleotide polymorphisms in sporadic amyotrophic lateral sclerosis.
Cereda C et al.
Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases, 2006
Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism.
Krueger SK et al.
Pharmacology & Therapeutics, 2005
The implications of polymorphisms in mammalian flavin-containing monooxygenases in drug discovery and development.
Cashman JR
Drug Discovery Today, 2004
Evaluation of xenobiotic N- and S-oxidation by variant flavin-containing monooxygenase 1 (FMO1) enzymes.
Furnes B et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology, 2004
Genetic variability at the human FMO1 locus: significance of a basal promoter yin yang 1 element polymorphism (FMO1*6).
Hines RN et al.
The Journal of Pharmacology and Experimental Therapeutics, 2003
Identification of novel variants of the flavin-containing monooxygenase gene family in African Americans.
Furnes B et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2003
Select a paper to view details